US In Vivo CAR-T Therapy Market Industry Trends and Forecast to 2034: Segmented by (Delivery, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$31.4 MnPlaceholder estimate
Estimate 2025$46.6 Mn41.4% of the global market
Projected 2034$1.62 Bn 3,369.5%Adds $1.57 Bn over 9 forecast years
CAGR 2025–203448.3%Faster than 99% of 180 Pharmaceuticals markets here
Key players5Companies profiled
US is 41.44% of the global market.
In North America, the largest is US (this report) at $46.6 Mn.
3 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US In Vivo CAR-T Therapy Market Analysis Executive Summary
In vivo CAR-T therapy delivers instructions straight into the body so a patient's own T cells become cancer fighters, without lab manufacturing.
Key segments of the in Vivo CAR-T Therapy market include delivery (Lentiviral Vectors, Lipid Nanoparticles and Targeted Viral Vectors) and indication (Blood Cancers, Autoimmune Diseases and Solid Tumors).
US In Vivo CAR-T Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US In Vivo CAR-T Therapy Market Dynamics
Market Growth Drivers
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the in Vivo CAR-T Therapy market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the in Vivo CAR-T Therapy market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the in Vivo CAR-T Therapy market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for In Vivo CAR-T Therapy Market in US
The in Vivo CAR-T Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for In Vivo CAR-T Therapy Market in US
In Vivo CAR-T Therapy in the US: rules, payment and research
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 3 studies on In Vivo CAR-T Therapy that are recruiting, active or about to start in the US.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for in Vivo CAR-T Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Delivery
4.2 By Indication
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Capstan Therapeutics (AbbVie)
7.2 Umoja Biopharma
7.3 Interius BioTherapeutics
7.4 Kelonia Therapeutics
7.5 EsoBiotec (AstraZeneca)
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The in Vivo CAR-T Therapy market can be segmented based on various criteria, including delivery, indication and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in In Vivo CAR-T Therapy right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
In Vivo CAR-T Therapy in context
The US compared
Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.
How big is the In Vivo CAR-T Therapy market in the US?
Placeholder estimate: about $46.6 Mn in 2025, rising to about $1.62 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the In Vivo CAR-T Therapy market in the US growing?
Placeholder estimate: about 48.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the In Vivo CAR-T Therapy market report cover?
The report splits the market by delivery (Lentiviral Vectors, Lipid Nanoparticles, Targeted Viral Vectors), indication (Blood Cancers, Autoimmune Diseases, Solid Tumors) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the In Vivo CAR-T Therapy market?
Key players include Capstan Therapeutics (AbbVie), Umoja Biopharma, Interius BioTherapeutics, Kelonia Therapeutics and EsoBiotec (AstraZeneca).
What is driving the In Vivo CAR-T Therapy market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the in Vivo CAR-T Therapy market.
Who regulates In Vivo CAR-T Therapy in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on In Vivo CAR-T Therapy are running in the US?
3 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on In Vivo CAR-T Therapy?
PubMed lists 24 papers on In Vivo CAR-T Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.